Niels W.C.J. van de Donk

Niels van de Donk uniquely bridges CD38-targeting antibodies and BCMA bispecifics for multiple myeloma. His senior authorship on the landmark 2015 NEJM paper demonstrating daratumumab monotherapy efficacy contributed to FDA approval of the first myeloma-specific antibody. His third-author position on MajesTEC-1 reflects Amsterdam UMC's critical contribution to teclistamab development. As Scientific Secretary of the European Myeloma Network and HOVON Multiple Myeloma Working Party Secretary, he shapes European myeloma research priorities. His 2017 Swammerdam Prize from the Dutch Society of Hematology recognized early-career excellence. With 300+ publications and 28,111 citations, van de Donk continues optimizing bispecific therapy safety through immunoglobulin supplementation research.

Niels van de Donk教授独特地连接了多发性骨髓瘤的CD38靶向抗体和BCMA双特异性抗体。他在2015年NEJM里程碑论文中展示daratumumab单药疗效的资深作者地位，促成了首个骨髓瘤特异性抗体的FDA批准。他在MajesTEC-1中的第三作者地位反映了阿姆斯特丹UMC对teclistamab开发的关键贡献。作为欧洲骨髓瘤网络科学秘书和HOVON多发性骨髓瘤工作组秘书，他塑造欧洲骨髓瘤研究优先事项。他2017年荷兰血液学会Swammerdam奖表彰了早期职业卓越表现。凭借300多篇出版物和28,111次引用，van de Donk继续通过免疫球蛋白补充研究优化双特异性抗体治疗安全性。